NVCR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVCR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
NovoCure's adjusted revenue per share for the three months ended in Mar. 2024 was $1.291. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.61 for the trailing ten years ended in Mar. 2024.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
As of today (2024-06-12), NovoCure's current stock price is $21.25. NovoCure's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $3.61. NovoCure's Cyclically Adjusted PS Ratio of today is 5.89.
During the past 11 years, the highest Cyclically Adjusted PS Ratio of NovoCure was 6.41. The lowest was 3.35. And the median was 4.22.
The historical data trend for NovoCure's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted Revenue per Share | Get a 7-Day Free Trial | - | - | - | 3.50 | 3.61 |
For the Medical Devices subindustry, NovoCure's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where NovoCure's Cyclically Adjusted PS Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, NovoCure's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 1.291 | / | 131.7762 | * | 131.7762 | |
= | 1.291 |
Current CPI (Mar. 2024) = 131.7762.
NovoCure Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.061 | 100.428 | 0.080 |
201412 | 0.053 | 99.070 | 0.070 |
201503 | 0.072 | 99.621 | 0.095 |
201506 | 0.079 | 100.684 | 0.103 |
201509 | 0.108 | 100.392 | 0.142 |
201512 | 0.148 | 99.792 | 0.195 |
201603 | 0.155 | 100.470 | 0.203 |
201606 | 0.210 | 101.688 | 0.272 |
201609 | 0.253 | 101.861 | 0.327 |
201612 | 0.349 | 101.863 | 0.451 |
201703 | 0.399 | 102.862 | 0.511 |
201706 | 0.435 | 103.349 | 0.555 |
201709 | 0.562 | 104.136 | 0.711 |
201712 | 0.600 | 104.011 | 0.760 |
201803 | 0.579 | 105.290 | 0.725 |
201806 | 0.674 | 106.317 | 0.835 |
201809 | 0.697 | 106.507 | 0.862 |
201812 | 0.749 | 105.998 | 0.931 |
201903 | 0.773 | 107.251 | 0.950 |
201906 | 0.900 | 108.070 | 1.097 |
201909 | 0.856 | 108.329 | 1.041 |
201912 | 0.999 | 108.420 | 1.214 |
202003 | 0.942 | 108.902 | 1.140 |
202006 | 1.077 | 108.767 | 1.305 |
202009 | 1.221 | 109.815 | 1.465 |
202012 | 1.295 | 109.897 | 1.553 |
202103 | 1.312 | 111.754 | 1.547 |
202106 | 1.290 | 114.631 | 1.483 |
202109 | 1.288 | 115.734 | 1.467 |
202112 | 1.282 | 117.630 | 1.436 |
202203 | 1.320 | 121.301 | 1.434 |
202206 | 1.346 | 125.017 | 1.419 |
202209 | 1.249 | 125.227 | 1.314 |
202212 | 1.223 | 125.222 | 1.287 |
202303 | 1.156 | 127.348 | 1.196 |
202306 | 1.186 | 128.729 | 1.214 |
202309 | 1.192 | 129.860 | 1.210 |
202312 | 1.251 | 129.419 | 1.274 |
202403 | 1.291 | 131.776 | 1.291 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.
For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
NovoCure's Cyclically Adjusted PS Ratio of today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 21.25 | / | 3.61 | |
= | 5.89 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
During the past 11 years, the highest Cyclically Adjusted PS Ratio of NovoCure was 6.41. The lowest was 3.35. And the median was 4.22.
Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.
Thank you for viewing the detailed overview of NovoCure's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Pritesh Shah | officer: Chief Commercial Officer | C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355 |
Michal Nath Puri | officer: Chief Human Resources Officer | BUSINESS VILLAGE D4, PARK 6/PLATZ10, ROOT V8 6039 |
Wilhelmus Cm Groenhuysen | officer: Chief Financial Officer | C/O NAVTEQ CORPORATION, 222 MERCHANDISE MART STE 900, CHICAGO IL 60654 |
Ashley Cordova | officer: Chief Financial Officer | 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355 |
Arye Barak Ben | officer: General Counsel | TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905 |
Timothy J Scannell | director | 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002 |
Kristin Stafford | director | 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087 |
Frank X Leonard | officer: President, CNS Cancers US | 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355 |
William Patrick Burke | officer: Chief Human Resources Officer | 195 COMMERCE WAY, PORTSMOUTH NH 03801 |
Uri Weinberg | officer: Chief Innovation Officer | NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355 |
Allyson J Ocean | director | 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087 |
Asaf Danziger | director, officer: Chief Executive Officer | 5 NACHUM CHAT ST., TIRAT HACARMEL L3 5112302 |
Ely Benaim | officer: Chief Medical Officer | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850 |
William F Doyle | director, 10 percent owner | |
Jeryl L Hilleman | director | C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
From GuruFocus
By Business Wire • 01-18-2024
By Business Wire • 11-28-2023
By Business Wire • 08-25-2023
By Business Wire • 10-15-2023
By GuruFocus Research • 10-30-2023
By Business Wire • 01-09-2024
By Business Wire • 08-29-2023
By GuruFocus Research • 08-28-2023
By Business Wire • 09-08-2023
By Business Wire • 10-12-2023